MedTrace Logo

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

NCT07170319 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-12-31

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

Conditions

  • Overweight or Obesity

Interventions

DRUG

IBI3032

IBI3032. Method of administration: oral, fasted administration.

DRUG

placebo

Placebo (without active ingredients). Method of administration: oral, fasted administration.

Sponsors & Collaborators

  • Innovent Biologics Technology Limited (Shanghai R&D Center)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2025-12-24
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07170319 on ClinicalTrials.gov